| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 529 | 10,739 | 1,764 | 1,339 |
| Research and development | 5,778 | 5,498 | 8,959 | 14,273 |
| General and administrative | 3,044 | 3,328 | 5,832 | 4,537 |
| Change in fair value of contingent consideration | 268 | 260 | 299 | 344 |
| Restructuring costs | 98 | 165 | 12,373 | 3,625 |
| Total operating expenses | 9,188 | 9,251 | 27,463 | 22,779 |
| Loss from operations | -8,659 | 1,488 | -25,699 | -21,440 |
| Interest income | 952 | 1,042 | 1,197 | 1,747 |
| Interest expense | 23 | 28 | 28 | 29 |
| Foreign exchange (loss) gain | -12 | 21 | 4 | 5 |
| Total other income | 917 | 1,035 | 1,173 | 1,723 |
| Net loss | -7,742 | 2,523 | -24,526 | -19,717 |
| Unrealized gain on available-for-sale securities | 58 | -21 | -31 | 218 |
| Comprehensive loss | -7,684 | 2,502 | -24,557 | -19,499 |
| Basic (in shares) | 191,778,950 | 191,551,282 | 190,707,085 | 188,997,194 |
| Basic (in usd per share) | -0.04 | 0.01 | -0.13 | -0.1 |
| Diluted (in shares) | 191,778,950 | 192,399,733 | 190,707,085 | 188,997,194 |
| Diluted (in usd per share) | -0.04 | 0.01 | -0.13 | -0.1 |
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)